What You Should Know:
- Maribel Health, a turnkey partner for health systems looking to design, build, and operate a full continuum of advanced home and community services, announced today the completion of a $25 million Series A funding round led by General Catalyst.
- The new funding will be used to accelerate growth with Maribel's initial partners, to attract and onboard the talent required to serve its collaborators worldwide and to support continued
Read More
Cancer | Digital Health Impact on Cancer Care | Policy, News, Analysis, Insights - HIT Consultant
Protai Raises $20M to Build an Oncology Drug Discovery Pipeline
What You Should Know:
- Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced a $12 million extension of its seed round, bringing the total amount to $20M.
- The round includes existing investors Grove Ventures and Pitango Healthcare and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai’s oncology drug discovery pipeline, expand data
Read More
H1 Launches Advanced Diversity and Clinical Trial Performance Insights
What You Should Know:
- H1, the connecting force for global healthcare provider, clinical, science, and research information, today announced the availability of indication-level diversity insights in addition to institution, provider, and patient diversity data within its Trial Landscape solution.
- Additionally, H1 has successfully onboarded its first customer – a top 20 pharmaceutical company – onto the H1 Data Network, a new solution that aggregates sponsor-contributed site and
Read More
Spectrum Taps Proscia to Modernize its Pathology Operations
- Proscia®, a leading provider of digital and computational pathology solutions, today announced that Spectrum Healthcare Partners (SHCP), an independent, multispecialty, physician-owned healthcare practice, has selected Concentriq® Dx to modernize its pathology operations. In adopting Proscia’s software platform, SHCP will increase access to high-quality diagnostic services across Maine and New Hampshire, better informing treatment decisions for more patients.
- Digital pathology, which
Read More
C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis of next-generation sequencing and exomes. The two companies have entered a collaboration agreement to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research.
- Under this agreement, RG will work with C2i Genomics to commercialize
Read More
Mayo’s Lucem Health Launches AI-Driven Early Disease Detection Platform
What You Should Know:
- Lucem Health™ today announced the availability of its new early AI-driven disease detection solutions, Lucem Health Reveal that leverages existing EHR data to identify patients who may be at a higher risk of serious or chronic disease.
- Reveal solutions surface previously undiscovered insights in readily available clinical data that can help provider organizations deliver greater clinical value for patients and more financial value to the organization.
Early
Read More
PathGroup Expands Operations with Proscia Concentriq Dx
What You Should Know:
- PathGroup, one of the largest providers of anatomic, clinical, digital, and molecular pathology services in the United States, is expanding its operations with Proscia's software platform (Concentriq® Dx) to further enhance the delivery of faster, higher quality results for millions of patients, helping to better inform treatment decisions.
- PathGroup currently supports more than 15,000 referring physicians and over 200 hospital
Read More
Tempus Forms Multi-omics Collaboration With Actuate Therapeutics
What You Should Know:
- Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone.
- This multi-omics approach is being used by Actuate Therapeutics in support
Read More
Addressing the Diversity Challenge in Clinical Research Through Patient Advocacy
Diversity is paramount to the success of clinical research, both ethically and scientifically. Without adequate representation of racial and ethnic minorities, investigators lack an understanding of the safety and efficacy of novel treatments within those groups. From a scientific standpoint, an incomplete dataset hinders drug delivery and the development of breakthrough therapies – but from an ethical standpoint, underrepresentation creates a barrier to treatment options for populations that
Read More
5 Components of a Patient-Centric eCOA Strategy for Oncology Clinical Trials
In the US alone, an estimated 1.9 million new cases of cancer were diagnosed in 2022, positioning oncology as a key subject of clinical research. Throughout oncology trial development, it is important that stakeholders acknowledge that only patients can fully understand the impact of treatment on their lives. Regulators are now looking beyond clinical indications such as tumor size and delayed disease progression. When evaluating the risks and benefits of treatment, they want to know whether the
Read More
